Key results from Calocurbs fourth human clinical study include the following: Calocurb is clinically shown to improve body composition by reducing body fat without losing muscle mass Average weight loss of 8.3 lbs (3.77 kg) after six months, compared to 0.88 lbs (0.4 kg) with the placebo group Over 6.5x greater reduction in body fat vs placebo Average body fat loss of 9.9 lbs (4.49 kg) vs 1.5 lbs (0.68 kg) after six months of consistent use of Calocurb vs placebo 3.5x greater reduction in visceral fat vs placebo Average visceral fat loss of 5 in 2 (32.5 cm2) vs 1.4 in 2 (9.1 cm2) lost after six months of consistent use of Calocurb vs placebo For over a decade, Calocurb has undertaken ground-breaking clinical research into Amarasate to continue bringing natural weight management solutions to those interested in GLP-1 and weight loss options
Gelotte & Zimmerman, 2015)
Our weight loss program in Austin, Texas employs weight loss experts who understand that each patient's body reacts differently to medications, and what works well for one person may not be suitable for another
In vitro and in vivo studies have confirmed that p53 can induce miR-1249 to inhibit colorectal cancer (CRC) growth, metastasis, and angiogenesis by targeting VEGFA and HMGA2 [40], indicating that the tumor suppressor p53 activates downstream genes via transcription under stress conditions
Sleep Apnea J 12(1):2334 Kow CS, Hasan SS, Naing L, Merchant HA (2025) Effects of GLP-1 receptor agonists on obstructive sleep apnea severity: a systematic review and meta-analysis of clinical trials
If you need more information about Exion
